Evidence map›Paper›PMID 37090303›Full record

ArticleCureus2023

Relationships Between Systemic Inflammatory Markers and 18F-FDG PET/CT Imaging and Clinical Findings in Pulmonary Sarcoidosis.

Tugce Sahin Ozdemirel, Berna Akıncı Özyürek, Ebru Tatci, Ozlem Ertan, Esma Sevil Akkurt, Aysegul Senturk, Ozlem Ozmen

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tugce Sahin OzdemirelPulmonary Medicine, Ankara Ataturk Sanatorium Training and Research Hospital, Ankara, TUR.
Berna Akıncı ÖzyürekPulmonary Medicine, Ankara Ataturk Sanatorium Training and Research Hospital, Ankara, TUR.
Ebru TatciNuclear Medicine, Ankara Ataturk Sanatorium Training and Research Hospital, Ankara, TUR.
Ozlem ErtanPulmonology, Ankara Ataturk Sanatorium Training and Research Hospital, Ankara, TUR.
Esma Sevil AkkurtPulmonology, Ataturk Sanatorium Training and Research Hospital, Ankara, TUR.
Aysegul SenturkPulmonology, Ankara Abdurrahman Yurtaslan Oncology Hospital, Ankara, TUR.
Ozlem OzmenNuclear Medicine, Ankara Ataturk Sanatorium Traning and Research Hospital, Ankara, TUR.
Ankara Onkoloji Eğitim ve Araştırma Hastanesi · TRAnkara Atatürk Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim Sarcoidosis is a multisystem inflammatory disease of unknown aetiology. This study aimed to evaluate the relationship between systemic inflammatory parameters, the systemic immune-inflammation index (SII) and the lymphocyte-to-monocyte ratio (LMR), and disease stage, clinical findings, and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) tomography/computed tomography (PET/CT) uptake. Materials and methods Our study included 73 patients. The general characteristics, radiological features, spirometric tests, PET/CT findings, and laboratory parameters of the patients were recorded. Results Relapse and parenchymal fibrosis were not associated with metabolic parameters, such as LMR and SII. Serum angiotensin-converting enzyme (ACE) levels were lower in the relapsed group than in the non-relapse group. However, the patients' PET/CT images indicated that 18F-FDG parenchym maximum standard uptake value (SUV max), lymph node SUV max, lymph node short axis dimension, SII, and LMR were similar between all patients, relapsed or not. Conclusion Although found to be significant in other inflammatory diseases, we found that SII and LMR alone did not indicate disease prognosis in sarcoidosis due to the small number of patients and the lack of homogeneity between the groups in our study. The usefulness of these markers for clinical use should be investigated by studies that include those with extrapulmonary sarcoidosis, and that calculate these markers at the time of disease diagnosis and during the post-treatment period.

Indexed as

18f-fdginflamationlmrsarcoidosissii index

Identifiers

PMID37090303
PMCPMC10120846
OpenAlexW4353059856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.